# A Real-World Study of Bispecific Antibodies in Multiple Myeloma

> **NCT06359067** · — · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 600 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **OTHER:** Treated by bispecific antibodies, teclistamab or elranatamab in usual care
- **OTHER:** Not treated by bispecific antibodies in usual care

## Key facts

- **NCT ID:** NCT06359067
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06359067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06359067, "A Real-World Study of Bispecific Antibodies in Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06359067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*